Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTRLMKF)

DTT Name	Phospholipase D2 (PLD2)
Synonyms	hPLD2; Phosphatidylcholine-hydrolyzing phospholipase D2; PLD1C; PLD 2; Choline phosphatase 2
Gene Name	PLD2
DTT Type	Clinical trial target	[1]
Related Disease	Coagulation defect [ICD-11: 3B10]
BioChemical Class	Phosphoric diester hydrolase
UniProt ID	PLD2_HUMAN
TTD ID	T10383
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
EC Number	EC 3.1.4.4
Sequence	MTATPESLFPTGDELDSSQLQMESDEVDTLKEGEDPADRMHPFLAIYELQSLKVHPLVFA PGVPVTAQVVGTERYTSGSKVGTCTLYSVRLTHGDFSWTTKKKYRHFQELHRDLLRHKVL MSLLPLARFAVAYSPARDAGNREMPSLPRAGPEGSTRHAASKQKYLENYLNRLLTMSFYR NYHAMTEFLEVSQLSFIPDLGRKGLEGMIRKRSGGHRVPGLTCCGRDQVCYRWSKRWLVV KDSFLLYMCLETGAISFVQLFDPGFEVQVGKRSTEARHGVRIDTSHRSLILKCSSYRQAR WWAQEITELAQGPGRDFLQLHRHDSYAPPRPGTLARWFVNGAGYFAAVADAILRAQEEIF ITDWWLSPEVYLKRPAHSDDWRLDIMLKRKAEEGVRVSILLFKEVELALGINSGYSKRAL MLLHPNIKVMRHPDQVTLWAHHEKLLVVDQVVAFLGGLDLAYGRWDDLHYRLTDLGDSSE SAASQPPTPRPDSPATPDLSHNQFFWLGKDYSNLITKDWVQLDRPFEDFIDRETTPRMPW RDVGVVVHGLPARDLARHFIQRWNFTKTTKAKYKTPTYPYLLPKSTSTANQLPFTLPGGQ CTTVQVLRSVDRWSAGTLENSILNAYLHTIRESQHFLYIENQFFISCSDGRTVLNKVGDE IVDRILKAHKQGWCYRVYVLLPLLPGFEGDISTGGGNSIQAILHFTYRTLCRGEYSILHR LKAAMGTAWRDYISICGLRTHGELGGHPVSELIYIHSKVLIADDRTVIIGSANINDRSLL GKRDSELAVLIEDTETEPSLMNGAEYQAGRFALSLRKHCFGVILGANTRPDLDLRDPICD DFFQLWQDMAESNANIYEQIFRCLPSNATRSLRTLREYVAVEPLATVSPPLARSELTQVQ GHLVHFPLKFLEDESLLPPLGSKEGMIPLEVWT
Function	May have a role in signal-induced cytoskeletal regulation and/or endocytosis.
KEGG Pathway	Glycerophospholipid metabolism (hsa00564 ) Ether lipid metabolism (hsa00565 ) Metabolic pathways (hsa01100 ) Ras signaling pathway (hsa04014 ) cAMP signaling pathway (hsa04024 ) Sphingolipid signaling pathway (hsa04071 ) Phospholipase D signaling pathway (hsa04072 ) Endocytosis (hsa04144 ) Fc gamma R-mediated phagocytosis (hsa04666 ) Glutamatergic synapse (hsa04724 ) GnRH signaling pathway (hsa04912 ) Parathyroid hormone synthesis, secretion and action (hsa04928 ) Pathways in cancer (hsa05200 ) Chemical carcinogenesis - reactive oxygen species (hsa05208 ) Pancreatic cancer (hsa05212 ) Choline metabolism in cancer (hsa05231 )
Reactome Pathway	Synthesis of PA (R-HSA-1483166 ) Role of phospholipids in phagocytosis (R-HSA-2029485 ) RAC1 GTPase cycle (R-HSA-9013149 ) RAC2 GTPase cycle (R-HSA-9013404 ) Synthesis of PG (R-HSA-1483148 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VU0364739	DMOI0TN	Coagulation defect	3B10.0	Clinical trial	[1]
------------------------------------------------------------------------------------

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

References

1	Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem. 2010 Sep 23;53(18):6706-19.
2	Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem. 1998 May 22;273(21):12846-52.